How effective is Delamanid in treating tuberculosis?

Delamanid(Delamanid) is a relatively new experimental drug that has shown efficacy against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis. It has been approved for the treatment of tuberculosis in the European Union (trade name: Deltyba) and Japan as part of combination therapy to treat multidrug-resistant tuberculosis.

Delamani is another very promising compound that has entered Phase 3 clinical trials. In a study reporting the effects of delamanid in combination with an optimized background regimen, a higher proportion of favorable outcomes was observed in the subgroup of XDR-TB patients treated long-term with delamanid (61.4%) compared with those treated with short-term medication (50%). Notably, all 44 patients with XDR-TB who received delamanid for at least 6 months survived. Although the clinical efficacy and safety of delamanib in small cohort studies appear promising, further clinical studies in larger subject groups are needed to validate these preliminary findings.

Delamani (OPC-67683) is a nitrodihydroimidazole derivative and a new anti-tuberculosis drug that inhibits mycolic acid synthesis and shows potent activity against drug-resistant strains of Mycobacterium tuberculosis in vitro and in vivo. There is an original research version in Russia, and each box is about 1 more than a thousand. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.